Chemotherapy has been used to inhibit cancer growth for decades, but emerging evidence shows it can affect the tumor stroma unintentionally promoting cancer malignancy. After treatment of primary tumors, remaining drug drains via lymphatics. Though all drugs interact with the lymphatics, we know little of their impact on them. Here, we show a previously unknown effect of platinums, a widely used chemotherapeutic, to directly induce systemic VEGFR3-dependent lymphangiogenesis. These changes are dose-dependent, long-lasting, and occur in healthy and cancerous tissue in multiple mouse models of breast cancer. We saw similar effects in human ovarian and breast cancer patients whose treatment regimens included platinums. Carboplatin treatment results in lymphatic hyperplasia and secretion of prochemotactic factors in lymph nodes. Carboplatin treatment of healthy mice prior to mammary tumor inoculation increases cancer metastasis. These findings have broad-reaching implications for cancer patients receiving platinums and support the inclusion of anti-VEGFR3 therapy into treatment regimens.
Introduction
Over 650,000 cancer patients receive chemotherapy in the United States every year, with platinums, taxanes, and anthracyclines representing the most common classes of drugs (1). Unfortunately, many of these patients suffer recurrence. In breast cancer, the second most common cause of cancer death in women in the US, mortality results from metastasis rather than primary tumor growth (2) . Ovarian cancer is similarly deadly due to dissemination of tumor rather than initial growth (3) . Despite the centrality of metastasis to patient outcomes, it remains unclear why tumors that appear to be controlled or even cleared by initial chemotherapy later recur.
Chemotherapeutic drugs enter the tumor via blood vasculature and drain through the stroma toward peritumoral lymphatics. Similarly, tumor cells metastasize from carcinomas primarily via the lymphatics and downstream lymph nodes (4) . Thus, the lymphatics represent a point of access for both tumor cells and chemotherapies to the rest of the body. Enlargement, sprouting, and proliferation of lymphatic vessels at both the primary tumor site (5, 6) and metastatic sites (7) are associated with increased cancer growth, metastasis, and poor prognosis (8) . Treatment of lymphangiogenic tumors with inhibitors of VEGF Receptor 3 (VEGFR3), which targets lymphatic endothelial cells (LECs), inhibits systemic metastasis (9, 10) .
Although chemotherapies pass through lymphatics, thus interacting with these gatekeeping vessels, little information is available on how chemotherapies affect them (9, 10) . Although one class of chemotherapy -taxanes -was shown to induce lymphangiogenesis in mice (10) , here we examine how the other major classes of chemotherapy impact the lymphatics, with an emphasis on platinum chemotherapy.
Platinum agents are some of the most commonly used chemotherapies in the United States and are currently administered to treat a variety of cancers (11) . Thus, we aimed to understand chemotherapeutic effects on the lymphatics.
Results

Lymphatic endothelial cells respond to platinum chemotherapy
We treated monolayers of human LECs with low doses of docetaxel, doxorubicin, or carboplatin.
Breakdown of LEC junctions is associated with vessel permeability, enhancing opportunities for tumor cells to intravasate (12) . We observed gaps in LECs treated with carboplatin ( Fig. 1A,B ), but not with doxorubicin or docetaxel (Fig. S1A,B) . Treatment with other platinum agents (cisplatin and oxaliplatin) showed similar phenotypes (Fig. S1C,D) . VEGFR3 activation can lead to phenotypic changes in LEC junctions (13) , and we saw increased phosphorylated VEGFR3 on carboplatin-treated LECs (Fig. 1C) .
Cellular adhesion molecules on LECs facilitate immune cell trafficking but are hijacked by tumor cells entering lymphatic vessels (13) . LEC monolayers treated with carboplatin displayed higher numbers of ICAM1+ cells in hotspot regions compared to vehicle (Fig. 1D,E) . Interestingly, platinum treatment (24h) did not diminish viability (Fig. 1F) ; in fact, it induced proliferation, a necessary precursor for in vivo lymphangiogenesis ( Fig. 1G, S1E,F) . Platinums were the only class of chemotherapy tested that induced significant proliferation in LECs (Fig. 1H) . Together, these data suggest that platinum chemotherapy acts directly on LECs to induce phenotypes indicative of lymphangiogenesis.
Gene set enrichment analysis of microarray data of treated LECs showed upregulated proliferation, survival, and neovascularization pathways ( Fig. 1I, Table S1 ). Carboplatin induced activation of the prosurvival and proliferation pathways MAPK, JAK-STAT, PI3K/AKT, RAS, and HIF1-a signaling in LECs.
Induction of these pathways, paired with increased expression of genes such as MTOR, INOS, ANGPT1, CMYC, PI3K, and others, may suggest platinums are activating growth factor signaling in LECs in response to cellular stress. Reverse phase protein array (RPPA) and pathway analysis indicated similar pathway upregulation, pointing to signaling via FGFR, VEGFR, and EGFR families (Table S2 ). Other enriched pathways included those governing cellular adhesion molecules, GAP junctions, and chemokine signaling, all important in LEC activation. Pathway enrichment analysis of the top upregulated microRNAs (9 in total, >2-fold increase in expression) showed similar pathway activation (Table S3 ). 
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Platinum chemotherapy induces dose-dependent and sustained lymphangiogenesis in healthy murine, rat, and human tissues
Building on these in vitro data, we tested lymphangiogenesis in physiologically relevant models. First, we used ex vivo rat mesentery tissue (14) to analyze impact of treatment on lymphatics within intact vascular networks ( Fig. 2A) . Carboplatin significantly increased sprouting of lymphatic vessels ( Fig. 2B-D) but not blood vessels ( Fig. S2A-C) .
The importance of lymphatics in mammary carcinoma progression is well-established. We treated healthy, non-tumor-bearing female mice with 0-3 doses of carboplatin (8 mg/kg/dose) to examine lymphangiogenesis in naïve mammary fat pads (MFP) ( Fig. S3A-D) , histologically quantifying lymphatic vessel density (LVD), area, and perimeter ( Fig. S3E-F) . Carboplatin treatment resulted in significant dosedependent increases in LVD in the MFP stroma of both Balb/c and SCID mice ( Fig. 2E, Fig. S3G ), but no significant increase in vessel area or perimeter ( Fig. S3G,H) . LVD remained elevated 8 weeks after final treatment with carboplatin comparable to that at day 3 ( Fig. 2F) .
Platinum chemotherapy is standard of care in high-grade serous ovarian cancer along with cytoreductive surgery. Because the omentum is the most frequent site of ovarian cancer metastasis, it is routinely removed during surgery, giving us access to histologically normal tissues. We analyzed lymphatics in omentum from patients treated with neoadjuvant carboplatin and docetaxel chemotherapy prior to surgery ( Table S4 ). All omentum samples were pathologist-identified as uninvolved and ostensibly healthy.
Histologically normal omentum treated with carboplatin had significantly higher LVD compared to that of untreated patients (Fig. 2G,H) . 
Platinum chemotherapy induces lymphangiogenesis in ovarian and breast tumor stroma
In cancerous omental tissue from 17 patients with or without carbotaxol treatment prior to surgery ( Fig.   3A , Table S5 ), we again detected a significant increase in LVD in patients receiving neoadjuvant platinums ( Fig. 3B) . Similarly, in primary tumor stromal tissue from 27 TNBC patients ( Fig. 3C, Table S6 ), there was a significant increase in LVD in patients treated with platinums prior to surgical resection ( Fig. 3D) .
Therefore, neoadjuvant chemotherapy that includes platinum corresponds with increased lymphangiogenesis in the human tumor stroma.
While ovarian cancers can spread through multiple mechanisms, breast cancer preferentially metastasizes via lymphatics (4) . Therefore, we employed a series of breast cancer mouse models to analyze platinum effects on tumor-associated lymphangiogenesis: orthotopic 4T1 syngeneic tumors (immunecompetent); orthotopic MDAMB231 xenograft (immune-compromised); or the inducible autochthonous
, which more closely mimics the malignant transformation and progression in humans (15) . Mice received carboplatin when tumors were palpable, and there were no difference in tumor size observed (Fig.   S4A ). Histological analysis ( Fig. 3E-H, Fig. S4B ,C) showed significantly increased LVD after three treatments of carboplatin ( Fig. 3I) . Unlike in naïve MFP, lymphatic vessel area and perimeter significantly increased in immunocompetent mice ( Fig. 3J, S4D ). 
Platinum-induced lymphangiogenesis primes the premetastatic niche for metastasis
Enlargement and remodeling of lymphatic vessels is known to increase tumor cell dissemination (6, 8, 16) with LVD and tumor spread correlating in murine and human cancers (17) (18) (19) . We hypothesized that priming of naïve tissues with carboplatin promotes tumor cell invasion and metastasis.
We treated healthy, tumor-naïve mice with systemic carboplatin to induce lymphangiogenesis ( Fig.   4A ), followed by orthotopic implantation of 4T1 tumor cells 1
week later. Though there was no 
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Vehicle Carboplatin significant difference in tumor size at endpoints ( Fig. S5A) , tumor cell metastasis to the tumor-draining inguinal lymph node (TDLN), considered a first step in tumor cell dissemination (4), significantly increased in platinum pre-treated TDLNs compared to control ( Fig. 4B-D) . Platinum-pretreated TDLNs had significantly higher LEC populations with platinum pretreatment, indicating lymphangiogenesis ( Fig. 4E) .
These data suggest that the lymphatics activated and remodeled by platinums are functionally capable of promoting metastasis. We also evaluated whether platinum-priming could contribute to distant metastases, e.g. to lung. 21 days after implantation, 100% of carboplatin pre-treated mice showed gross lung metastases, compared to 50% of the vehicle. Microscopic examination of lungs showed significantly increased numbers of foci ( Fig. 4G ) that were significantly larger with pretreatment ( Fig. 4H) . Therefore, priming tissues by carboplatin-induced lymphangiogenesis promotes LN and lung metastasis.
Carboplatin yields an inflamed lymph node phenotype with increased lymphangiogenesis
Lymphangiogenesis is considered a critical component of premetastatic niche formation, especially in the lymph node, a highly lymphovascularized organ ripe for metastatic colonization. Carboplatin treatment of LNs from tumor-naïve mice resulted in larger LNs with hyperplastic lymphatics and increased podoplanin staining ( Fig. 5A, Fig. S6A,B) , with a significant increase in LEC number ( Fig. 5B) . Each of these phenomena has been associated with LN inflammation and tumor metastasis (20) .
The expansion of lymphatics led us to examine the relationship between LECs and the LN microenvironment with treatment. We also wanted to define the effects of platinum on other cell populations in the context of an intact lymph node. To do this, we used a unique ex vivo lymph node slice model ( Fig. 5C) where each slice represents a distinct section of the lymph node with associated differences in cellular and extracellular composition. Representative slices from Prox1-GFP mice showed qualitative increases in lymphangiogenesis ( Fig. 5D) , though imaging-based quantification was difficult. Flow cytometry of cells from single slices confirmed that carboplatin treatment of slices significantly increased the LEC population but not the BEC, fibroblastic reticular cell, or T cell populations ( Fig. S6C-E ). In addition to providing more inlets and outlets for tumor cell dissemination, lymphangiogenesis can also increase metastasis through tumor-stimulating chemoattractants secreted by LECs. In a 3D tissueengineered model of the lymphatic-stroma interface (10), carboplatin-exacerbated invasion of tumor cells was wholly dependent on LEC presence (Fig. S5B,C) indicating a chemotactic mechanism. In untreated slices, the number of LECs negatively correlated with the node's corresponding levels of IL-6 (r= -0.4533) ( Fig. 5E ) and CCL21 (r= -0.3673) ( Fig. 5F) . With carboplatin treatment, trends flipped, and LEC number positively correlated with IL-6 (r=0.3749) and CCL21 (r=0.4987). These cytokines weakly correlated with numbers of blood endothelial cells (BECs) with correlation trends remaining nearly identical with treatment ( Fig. 5G,H) . Other cytokines (TNFα, CXCL10) were weakly correlated with LECs but did flip with treatment ( Fig. S6F,G) . The number of T cells significantly correlated with the number of LECs in slices only when treated with carboplatin (r=0.6227, p<0.05) compared to vehicle (r=0.4179, p=0.176), potentially explaining, in part, the expansion of the lymph nodes seen in vivo (Fig. S6H) . Collected carboplatin-treated slice supernatants elicited significantly more 4T1 invasion as compared to vehicle ( Fig.   5I,J) .
We hypothesized that priming also occurred in lung to promote chemotaxis similar to LN. As an ex vivo model of the lung was not readily available, we chose to treat healthy, tumor-free mice in vivo with carboplatin, similar to previous experiments, harvesting, digesting, and decellularizing lymph nodes and lungs three days after the final treatment ( Fig. S7) . Tumor cells invaded significantly more to carboplatintreated lymph node (Fig. 6A) and lung (Fig. 6B) digested and decellularized tissues. These data suggest that platinum chemotherapy primes the premetastatic niche for subsequent tumor invasion.
Platinum-induced lymphangiogenesis and metastasis are inhibited through inhibition of VEGFR3
Having shown carboplatin treatment increases invasion and metastasis, we sought the underlying mechanism. VEGFR3 blockade reduces metastatic spread and lymphangiogenesis in a number of tumor models, as the VEGFC:VEGFR3 signaling pathway is one of the quintessential drivers of LEC proliferation (6) . Our in vitro studies (Fig. 1C,I) led us to hypothesize that VEGFR3 is involved in carboplatin-mediated lymphangiogenesis and metastasis. Thus we aimed to conduct our prior studies in the presence of anti-VEGFR3 blocking with an antibody or IgG control antibody.
In our prior invasion assay toward carboplatin-primed lungs/LN, addition of anti-VEGFR3 significantly attenuated platinum-induced invasion of 4T1 cells toward both tissue homogenates (Fig.   6A,B) . In our ex vivo LN slice model (Fig. 5C) , addition of anti-VEGFR3 significantly reduced the LEC numbers increased by carboplatin ( Fig. 6C) , with no effects on BECs (Fig. S8A) . Corresponding reversal of chemokine secretion was seen (Fig. S8B) . This data suggests that VEGFR3-activated LECs is directly responsible for platinum-induced priming of the premetastatic niche.
Ultimately, metastasis reduction in vivo is desired. Alternating carboplatin treatment with anti-VEGFR3 therapy (Fig. S8C,D) resulted in reversion of metastastic spread induced by carboplatin in KRas G120D p53 fl/fl p110α myr mice (Fig. 6D,E) . Correspondingly, we could reverse carboplatin-mediated increases in LVD (Fig. 3I) in both 4T1 (Fig. S8E) and KRas G120D p53 fl/fl p110α myr (Fig. 6F) tumor-bearing fat pads. Similarly, blockade significantly reduced tumor-associated vessel area (Fig. S8F,H) and perimeter ( Fig. S8G,I) . Moving to naïve tissues (Fig. 2F) , anti-VEGFR3 reduced platinum-increased LVD in naïve MFPs (Fig. 6G) , though the effect was stronger in tumor-bearing fat pads. Together, these data indicate that carboplatin-associated lymphangiogenesis occurs via a VEGFR3-dependent mechanism and therapeutic inhibition of this pathway is a viable solution to preventing these phenomena.
To loop back to our initial observations, we used MAZ51 (3-(4-Dimethylamino-naphthalen-1ylmethylene)-1,3-dyhydro-indol-2-one), a specific small molecule inhibitor of VEGFR3, on monolayers of LECs. MAZ51 had little effect on LEC proliferation alone, but significantly suppressed carboplatin-induced LEC proliferation ( Fig. 6H) and junctional disruption (Fig. 6I) to resemble untreated LECs (Fig. 1) . Thus, VEGFR3 inhibition can directly revert the phenotypic effects of carboplatin seen in vitro, ex vivo, and in vivo, thereby explaining its therapeutic success. 
Ex vivo LN Slice
Discussion
Here we see that platinum agents increase lymphatic expansion, proliferation, and expression of surface and secreted proteins, all of which are well-correlated with increases in tumor metastasis across a number of models (6) . It is counterintuitive that chemotherapies would induce expansion of a cellular population and promote tumor progression, however, in fibroblasts, induction of stress responses by DNAdamaging chemotherapies can result in similar activation and compensatory proliferation (21, 22) . In addition to their well-known target of DNA, platinum chemotherapies have also been found to target cytoskeletal proteins, altering biological functions and potentially explaining our observed junctional changes (23) . It has also been demonstrated that cisplatin can increase expression of VEGFR1 on VCAM1expressing endothelial cells, though enhanced metastasis of primary tumor was not seen as we demonstrate here (24) .
Lymphangiogenesis not only impacts tumor cells but also the stroma and immunity. Fluid drainage triggered by lymphangiogenesis can increase migration and trafficking of tumor cells, dendritic cells, and macrophages (25) . Increased fluid flow activates fibroblasts yielding stromal collagen deposition and reorganization which can increase tumor cell invasion (26) . LVD increased in both tumor and naïve fat pads while lymphatic vessel enlargement only occurred in tumor. It is possible that the increased fluid flow and cytokine production elicited by the tumor may exacerbate lymphatic dilation in this context (6, 8, 16) .
The proliferation of T-cells and LECs seen ex vivo may contribute to the lymph node growth seen in vivo, but cellular migration and infiltration from the tissue is likely more influential. The implications of lymphangiogenesis to tumor immunity is vast as lymphatics actively participate in tumor tolerance via numerous mechanisms, including a dependency on CCL21/CCR7 interactions (27, 28) . Therefore, increased LECs in lymph nodes after treatment could enhance tolerance in this metastatic organ, potentially dampening T cell responses, though we did not directly examine this. As platinum chemotherapy in some in vitro cases, can activate T cells, the consequences of increased tolerogenic LECs may interfere with this possible benefit (23) . Conversely, lymphatics are critical in inflammation where increased cellular adhesion molecules, chemokine secretion, and permeability encourage lymphatic-immune interactions. While we did not directly examine this in our studies, these phenomena promote the migration of immune cells such as macrophages and dendritic cells in inflammation and disease progression (29) .
All therapies, anti-cancer or otherwise, eventually drain via our lymphatic system, but the majority of research has focused on the impacts of drugs on the blood vasculature, largely ignoring the impact on this endothelium (30) . Research into specifically targeting lymphatics for treatment purposes is growing, without corresponding growth into how therapies directly affect the lymphatics themselves (31, 32) .
Targeting of the lymph nodes with chemotherapy has been suggested as a potential treatment for metastatic spread (33) . However, this study did not show efficacy, only an ability to target potential metastatic nodes.
Though these strategies are not without merits, targeting of the lymphatic system and lymph nodes should be holistically studied in order to prevent inadvertent detrimental side effects as we highlight here. Indeed, more studies are emerging that suggest chemotherapy may paradoxically counteract its own efficacy through action on either the tumor cells or its associated stroma. Chemotherapies have myriad off-target effects, including enriching for cancer stem cell populations (34) , promoting invasiveness (35) , and inducing epithelial-to-mesenchymal transition (EMT) to encourage drug resistance (36) . Last, ilation of vessels, as seen here, is associated with leakiness, and impaired pumping ability (6, 8, 16) indicating that there may be effects on other lymphatic malignancies, such as lymphedema. Regardless, off-target effects of these common cytotoxic agents certainly warrant further investigation.
Our studies describe a previously unknown pro-lymphangiogenic action of platinum chemotherapeutics that results in enhanced metastasis and reduced efficacy. These counter-therapeutic events are dependent on VEGFR3 and, therefore, supplementing chemotherapeutic regimens with anti-VEGFR3 was sufficient to prevent them. We believe that these findings highlight our incomplete understanding of chemotherapeutic action in the tissue stroma. Our data here suggest that informed pairing of chemotherapy with targeted therapies to the tumor microenvironment may improve overall efficacy, allowing chemotherapeutic cytoreductive benefits without unintended off-target effects that may lead to deadly recurrence. Specifically, we believe these studies may renew interest in the clinical potential of anti-VEGFR3 therapy, such as IMC-3C5 (37) , which is well-tolerated, yet stalled in clinical trials, and may show promising results when used in combination with specific chemotherapy within the proper disease context. Cell lines were tested for mycoplasma and all experiments were completed afterwards.
Materials and Methods
Cell culture
In vitro drug treatment, immunocytochemistry, and live/dead assays
LECs were cultured on glass coverslips in complete media as described above; the LEC monolayer was treated with 1 µM carboplatin, cisplatin, oxaliplatin, docetaxel, doxorubicin, MAZ51(38), or appropriate solvent control (referred to as 'vehicle') for 6 hours (phenotypic studies) or 48 hours (live/dead analysis).
After treatment, coverslips were fixed with 4% paraformaldehyde (PFA) for 30 minutes at room temperature and underwent immunofluorescent staining with Ki67 to assess proliferation (Millipore, Cat. 
Reverse-phase protein array and pathway analysis
Human LECs were treated in vitro with 1 µM carboplatin for 6 hours. Cells were washed and lysed using RIPA buffer with protease and phosphatase inhibitors. RPPA was performed by the MD Anderson Functional Proteomics Core Facility as previously published (41) . To assess which proteins reacted to the treatment, ratios of brightness were calculated and the distribution was assessed. Outlier proteins, for which the ratio was more than 2 standard deviations from the mean of the ratio distribution, were taken to be most affected by the treatment. Pathway enrichment analysis for these proteins was performed using ConsensusPathDB (42) online tool and pathways enriched with statistical significance of unadjusted pvalue of 0.01 were retained for further analysis.
Harvest, treatment, and whole mounting of ex vivo rat mesentery tissues
Mesentery tissues were harvested from rats as previously described by Azimi, et al(14, 43) ( Fig. 2A) .
Briefly, mesenteric tissue was harvested from the small intestine of an adult Wistar rat and transferred into a culture dish. Tissues were arranged on permeable membranes of cell crown inserts and cultured in MEM with 20% FBS and 1% penicillin/streptomycin for five days as previously described with 1 µM carboplatin or vehicle control. Tissues were then removed from inserts, grossed, mounted to slides, and fixed with methanol to undergo immunofluorescent staining with PECAM-1/CD-31 (BD Biosciences, Cat. #555026)
for blood vessels and LYVE-1 (AngioBio Co., Cat. #11-034) for lymphatic vessels. Images were taken of a minimum of five random areas of vessel remodeling for each well and quantified by counting the number of sprouts normalized to vessel area in each field.
In vivo animal study design
Studies in healthy, tumor-naive animals -6-week-old female Balb/c mice were treated via tail vein injection of carboplatin unless otherwise noted. Mice underwent three total treatments with 8 mg/kg carboplatin or vehicle control (saline); each treatment was three days apart and mice were euthanized CO2 inhalation three days following the final treatment. Naïve mammary fat pads and axillary lymph nodes were harvested; fat pads were post-fixed in 4% PFA for 24 hours, dehydrated, paraffin-embedded, and sectioned at 7-micron thickness to undergo immunohistrochemical staining (see Immunohistochemistry). Axillary lymph nodes were digested (dissociation as previously described (44) ) and total LEC counts quantified (see Flow Cytometry).
Studies in 4T1 breast cancer model -4T1 mouse mammary carcinoma cells were cultured as described above. 4T1 cells were suspended in 3.3 mg/ml growth-factor reduced basement membrane extract (Cultrex) For priming experiments, naïve mice were treated with three rounds of carboplatin as previously described and drug was allowed one week to clear(45). 10,000 4T1 cells were then injected as described above and allowed to grow until desired size endpoints were reached. Tumor-bearing fat pads were harvested and processed as described above. Lungs were removed, washed in saline, and fixed in 4% PFA for 48 h where they were then embedded in OCT and cryosectioned to undergo histological staining to examine metastasis. of Virginia. Mammary tumors were initiated by intraductal injection of adenovirus-Cre in these mice as previously described (15) . Tumor growth was tracked via weekly caliper measurements. Once tumor growth became palpable, mice were randomized into groups with normalization of tumor size across groups, followed by the initiation of treatment. Animals were treated with 3 doses of IV carboplatin (8 mg/kg) or vehicle staggered by one day with 3 doses of anti-VEGFR3 antibody (100 µg) or IgG control as described above once tumors were palpable. Mice were euthanized by CO2 inhalation when largest tumors reached 2 cm in any direction; tumor-bearing and contralateral naïve fat pads were collected for histology as described above.
Studies in transgenic breast
Studies in human xenograft breast cancer model -Human MDA-MB-231 breast cancer cells were cultured as described above. 1x10 6 cells were suspended in 3.3 mg/ml growth-factor reduced matrigel in phosphatebuffered saline (PBS) and orthotopically injected in a subareolar fashion into the fourth mammary fat pad of immunocompromised female mice (NOD.CB17-Prkdcscid/J). Once tumors were palpable, carboplatin was administed in three injections as described above. Mice were euthanized by CO2 inhalation one week following final treatment; tumor-bearing and contralateral naïve fat pads were processed for histology as described above. 
Human tissue sample acquisition
Immunohistochemistry
Tumor-bearing mammary fat pads and lung tissues were dissected from mice and post-fixed in 4% PFA for 48 hours at 4°C; naïve fat pads underwent 24 hours of fixation. Fat pads were transferred to 70% ethanol for 24 hours, dehydrated, and paraffin-embedded. Tissues were sectioned at 7 μm thickness. Sections were stained with anti-podoplanin antibody (1 μg/ml, R&D Systems) followed by ImmPRESS HRP anti-goat IgG peroxidase/SG peroxidase detection (Vector Labs) and nuclear counter-staining with hematoxylin (Vector Labs) was performed. Human samples were processed and stained similarly. Slides were scanned at 20X on an Aperio Scanscope. For quantification of lymphatic vessel size, a custom interactive MATLAB (MathWorks) program utilizing the Image Processing Toolbox (MathWorks) was designed to identify and analyze lymphatic vessels. First, IHC images were binarized using an intensity threshold capable of isolating vessels with high specificity. Next, a flood-fill operation was used to uniformly fill the vessel area.
These regions were then extracted for analysis. Vessels not captured or incompletely captured by the automated procedure were identified by user-drawn regions of interest (n=5/cohort, minimum of 20-30
representative vessels/cohort). Centroid coordinates, perimeter, and area was computed for each vessel. For lymphatic vessel density, all lymphatic (podoplanin+) vessels in the mammary fat pad were counted and vessel number was normalized to size of stromal area for each mouse to assess lymphatic vessel density as lymphatic vessel #/mm 2 stroma. Intratumoral lymphatic vessels were rare and not included in these analyses in animal models. For lymphatic metastasis, sections were stained with anti-GFP antibody (5 μg/ml, Thermo Fisher, RFP Tag Monoclonal Antibody RF5R) and whole node confocal scans were used to quantify percent metastatic area of total node via image thresholding in ImageJ. Lungs were cryopreserved and embedded in OCT following fixation, cryosectioned, and stained with hematoxylin and eosin (H&E) to detect metastasis. Macroscopic metastatic lesions were counted by eye, whereas whole 20X scans of lung tissue were taken to detect micrometastatic lesions. Area of macroscopic lesions were measured in ImageJ.
Ex Vivo Lymph Node Culture and Treatment
Lymph Node Harvest, Processing, and Culture
All animal work was approved by the Institutional Animal Care and Use Committee at the University of Virginia. Lymph nodes from female mice were collected and sliced as previously reported (46 
Luminex Analysis
A specialized premixed multiplex kit (R&D Systems, lot: LXSAMSM-4) was formulated to examine murine CCL21/6Ckine (BR72), IL-6 (BR27), CXCL10/IP-10 (BR37) and TNF-alpha (BR14). Supernatant application, inserts were processed for invasion analysis (10, 47) . All experimental conditions were run as triplicate samples in individual inserts.
Invasion Assays
Tissue engineered 3D model of human breast tumor microenvironment: After gel was removed, tissue culture inserts were washed briefly in phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde. Inserts were stained with DAPI and visualized by fluorescence microscopy. Cancer cells (DAPI + Cell Tracker Deep Red+) were counted in five individual fields per well. Percent cancer cell invasion was calculated as previously described. Three technical replicates were averaged for each experimental run to give a single biological replicate value for statistical analysis.
Ex vivo lymph node supernatants: For invasion assays, 100,000 4T1 cells were resuspended in a 1.8 mg/ml collagen I (rat tail collagen, Corning), 0.2 mg/ml basement membrane extract (reduced growth factor, Trevigen) matrix which were loaded into a 96-well tissue culture insert plate (Corning). Supernatants were placed in the lower chamber and cells invaded for 18h before gels were removed. Membranes were fixed and stained with DAPI and cells quantified to calculate total percent invasion based on total cells counted/total cells seeded.
Tissue homogenates from treated mice: Tissues from mice treated with 3 doses of carboplatin (as described above) were perfused with saline and dissected out. These tissues were degraded using 0.1 mg/ml Liberase TM for 30 minutes at 37C and then centrifuged down. The supernatant was removed and snap frozen until use. These samples were analyzed using BCA assay (Pierce) to determine total protein content. For the invasion assay of 4T1 cells (as above with lymph node slice supernatants) 25µg was added to the lower well.
Flow Cytometry on In Vivo Tissues
Cells from in vivo digested lymph nodes and lungs were dissociated as previously described and stained with live/dead reactive dye, anti-mouse CD45 PerCP-Cy5.5 (eBioscience), anti-mouse CD31 FITC (eBioscience), and anti-mouse gp38 PE-Cy7 (eBioscience). Flow cytometry samples were processed using the Millipore Guava easyCyte 8HT Flow Cytometer and analyzed using InCyte software for total LEC counts per mg as well as percentage of LECs. Gating was done first on live cells, followed by CD45populations. This subpopulation was gated for gp38 and CD31 with the following populations: CD31+gp38+ (LECs); CD31+gp38-(blood endothelial cells), and CD31-gp38+(fibroblastic reticular cells).
Statistical Analysis
All data are presented as mean ± standard error of the mean (SEM). One-way or two-way ANOVA followed by Tukey's multiple comparison test was used for statistical analysis of unmatched groups. Two group comparisons of normally distributed data as assessed by QQ plots were performed using unpaired t tests (with Welch's correction if standard deviations were unequal), while comparisons of non-normal data were performed using Mann-Whitney U tests. Statistical analyses were run using Graphpad Prism software.
p<0.05 is considered statistically significant. All in vitro assays were performed with a minimum of three biological replicates unless otherwise noted, murine study numbers are noted in legends and by individual graphed data points. Graphs were generated using Graphpad Prism software and are shown with mean +/standard error.
Figure Generation
Figures were generated using Adobe Creative Suite (Photoshop and Illustrator). Schematics were generated using BioRender.
